These include the development of features of SSc in chronic graft-versus-host disease (cGVHD) in humans, which is largely mediated by donor T cells and reversal of fibrosis and vasculopathy after autologous hematopoietic CD34+ stem cell treatment of patients with SSc (187, 188). This evidence concerns the gene CD34 and systemic sclerosis.